Dicerna Pharmaceuticals Price to Book Ratio 2012-2021 | DRNA

Historical price to book ratio values for Dicerna Pharmaceuticals (DRNA) over the last 10 years. The current price to book ratio for Dicerna Pharmaceuticals as of October 22, 2021 is 15.11.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Dicerna Pharmaceuticals Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-22 21.83 15.25
2021-06-30 37.32 $1.43 26.07
2021-03-31 25.57 $1.65 15.49
2020-12-31 22.03 $1.82 12.12
2020-09-30 17.99 $2.06 8.74
2020-06-30 25.40 $2.18 11.64
2020-03-31 18.37 $2.41 7.62
2019-12-31 22.03 $2.13 10.36
2019-09-30 14.36 $1.97 7.31
2019-06-30 15.75 $2.34 6.72
2019-03-31 14.65 $2.63 5.57
2018-12-31 10.69 $2.94 3.63
2018-09-30 15.26 $2.53 6.04
2018-06-30 12.25 $1.22 10.03
2018-03-31 9.56 $1.70 5.63
2017-12-31 9.03 $1.96 4.61
2017-09-30 5.75 $-0.18 -31.72
2017-06-30 3.17 $0.64 4.97
2017-03-31 3.40 $1.40 2.43
2016-12-31 2.88 $2.00 1.44
2016-09-30 5.88 $2.56 2.30
2016-06-30 3.00 $3.13 0.96
2016-03-31 5.36 $3.77 1.42
2015-12-31 11.87 $4.42 2.69
2015-09-30 8.21 $5.06 1.62
2015-06-30 13.95 $5.77 2.42
2015-03-31 24.03 $4.87 4.94
2014-12-31 16.47 $5.53 2.98
2014-09-30 12.73 $6.24 2.04
2014-06-30 22.57 $6.77 3.34
2014-03-31 28.25 $7.28 3.88
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.697B $0.164B
Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76